Pharmigene, Inc.

As of June 30, 2026, Pharmigene, Inc. carries a market capitalization of 366.88M, placing it among publicly traded companies globally. Its enterprise value stands at 910.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharmigene, Inc. has 50.47M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Pharmigene, Inc. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Pharmigene, Inc.'s stock has declined approximately 27.36% over the past 52 weeks. The 50-day moving average sits at 7.26, while the 200-day moving average is 8.71.

As of June 30, 2026, Pharmigene, Inc. holds 92.58M in cash and equivalents against 636.45M in total debt, resulting in a net debt position of 544.99M. Total book value stands at 260.29M, with working capital of 71.56M providing operational flexibility.